Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...

When patients consider joining clinical trials, we often assume their decisions are logical—balancing risks and benefits. In reality, emotions like fear, hope, trust, and personal history play a far ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

FUJIFILM Diosynth Biotechnologies, a leading global contract development and manufacturing organization (CDMO) with a significant presence in North Carolina, has entered into a landmark agreement with ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...